Log In
Print
BCIQ
Print
Print this Print this
 

BIND-014

  Manage Alerts
Collapse Summary General Information
Company Bind Therapeutics Inc.
DescriptionPolymeric nanoparticle containing docetaxel that concentrates in the neovasculature surrounding tumors and targets prostate-specific membrane antigen (PSMA; FOLH1; GCPII)
Molecular Target Prostate-specific membrane antigen (PSMA) (FOLH1) (GCPII)
Mechanism of ActionBinds prostate-specific membrane antigen (PSMA)
Therapeutic ModalityNanotherapy: Protein-based nanoparticles

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Get a free BioCentury trial today